SYD985 TREATMENT OF T-DM1 REFRACTORY CANCER PATIENTS

The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KOPER, NORBERT PETER, VOORTMAN, GERRIT
Format: Patent
Sprache:eng ; pol
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patients.